Uroplasty to Issue Third Fiscal Quarter Results on February 1, 2010

Share Name	Share Symbol	Market	Type
Uroplasty Common Stock	AMEX:UPI	AMEX	Ordinary Share

Share Name

Share Symbol

Market

Type

Uroplasty Common Stock

AMEX:UPI

AMEX

Ordinary Share

Price Change

% Change

Share Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.00

Uroplasty to Issue Third Fiscal Quarter Results on February 1, 2010

20/01/2010 11:00am

PR Newswire (US)

Uroplasty (AMEX:UPI)
Historical Stock Chart

From May 2019 to May 2024

MINNEAPOLIS, Jan. 20 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI) announced today that it will release financial results for the third fiscal quarter ended December 31, 2009, at the market close on Monday, February 1, 2010. The Company will host a conference call to discuss these results on Monday, February 1, 2010 at 3:30 p.m. Central Time. David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-8610. An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) and 303-590-3030 (international), with the passcode 4203310#. About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is on sales growth in the U.S. market. We offer the Urgent PC® system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique® Implants, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://www.uroplasty.com/. For Further Information: Uroplasty, Inc. EVC Group David Kaysen, President and CEO, or Doug Sherk/(Investors) Medi Jiwani, Vice President, CFO, and 415.896.6820 Treasurer, 952.426.6140 Chris Gale/Steve DiMattia (Media) 646.201.5431 DATASOURCE: Uroplasty, Inc. CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, +1-952-426-6140, both of Uroplasty, Inc., or Investors, Doug Sherk, +1-415-896-6820, or media, Chris Gale or Steve DiMattia, +1-646-201-5431, both of EVC Group for Uroplasty, Inc. Web Site: http://www.uroplasty.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

UPI Uroplasty Common Stock